查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138355

全球免疫蛋白诊断测试市场2022-2029

Global Immunoprotein Diagnostic Testing Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

由于肥胖、类风湿性关节炎、癌症、2 型糖尿病、传染病和心血管疾病的患病率不断上升，免疫蛋白诊断测试市场正在增长。

技术进步和肥胖、类风湿性关节炎和癌症患病率的上升预计将推动市场增长。

根据世界卫生组织 (WHO) 的数据，到 2020 年，慢性病将占全球所有死亡人数的近四分之三，其中 71% 死于缺血性心脏病 (IHD)，75% 死于中风，70糖尿病死亡的百分比预计发生在发展中国家。发展中国家的糖尿病患者人数预计将增加 2.5 倍以上，从 1995 年的 8400 万增加到 2025 年的 2.28 亿。在全球范围内，估计 60% 的慢性病负担发生在新兴经济体。事实上，印度和中国发生的心血管疾病仍然比世界上所有经济发达国家的总和还要多。不仅目前超重和肥胖的患病率已经达到前所未有的水平，而且在大多数发展中地区，这一比例每年都在增加。这种现像对公共卫生的影响是巨大的，并且已经变得显而易见。因此，慢性病的增加增加了对快速诊断的需求。

不断增长的老年人口和高发病率正在推动全球免疫蛋白诊断测试市场的增长。此外，对免疫蛋白诊断检测的需求不断增长，也可归因于全球传染病的流行。不卫生的生活条件，特别是在欠发达地区，也是导致疾病和传染病的一个因素。出于这个原因，免疫蛋白诊断测试的全球市场正在上升。

预计诊断测试的高成本将阻碍市场增长。

监管框架非常复杂，许多免疫蛋白诊断测试不容易获得批准，一些诊断测试的高成本可能会阻碍市场增长。

行业分析

全球免疫蛋白诊断测试市场根据波特五力、监管分析、供应链分析、定价分析、产品创新和未满足需求等各种行业因素对市场进行深入分析。

全球免疫蛋白诊断测试市场报告提供大约 45 多个市场数据表、40 多个数字和 180 页。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 技术进步，肥胖、类风湿性关节炎和癌症的患病率增加
    • 限制因素
      • 设备和维护成本高
      • 手术受伤的风险
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 监管分析
  • 供应链分析
  • 定价分析
  • 产品创新
  • 未满足的需求

第 6 章按测试类型

  • 免疫球蛋白诊断测试
  • C-反应蛋白 (CRP) 诊断试剂
  • 补体系统蛋白诊断剂
  • 免费轻链诊断剂
  • 结合珠蛋白诊断剂
  • 前白蛋白诊断剂
  • 其他

第 7 章按应用程序

  • 自身免疫性疾病检测
  • 传染病测试
  • 肿瘤学测试
  • 过敏测试
  • 毒理学测试

第 8 章技术

  • 基于□的免疫测定
  • 放射免疫分析
  • 免疫蛋白电泳
  • 化学发光法
  • 免疫荧光检测
  • 免疫比浊法
  • 其他

第 9 章，最终用户

  • 医院和诊所
  • 诊断实验室
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 测试类型基准测试
  • 值得关注的重点公司列表

第 12 章公司简介

  • Abbott Laboratory
    • 公司概况
    • 测试类型测试类型组合和描述
    • 主要亮点
    • 财务摘要
  • Thermo Fisher Scientific Inc
  • Bio-Rad Laboratories, Inc
  • Danaher Corporation
  • F. Hoffmann-La Roche Ag
  • Enzo Biochem, Inc
  • Siemens Aktiengesellschaft
  • Ortho Clinical Diagnostics
  • Diasorin S.P.A
  • Abcam Plc

第13章 全球免疫蛋白诊断测试市场-DataM

简介目录
Product Code: DMBT2306

Market Overview

Immunoprotein Diagnostic Testing Market size was valued US$ 11,480.26 million in 2021 and is estimated to reach US$ 20,938.71 million by 2029, growing at a CAGR of 7.9% during the forecast period (2022-2029).

Immunoprotein diagnostic testing is a diagnostic procedure that detects the level of immunoproteins in the body to analyze certain proteins such as immunoglobulin and pre-albumin. With continuous development in technologies, the immunoprotein diagnostic testing market is booming globally. These innovative technologies shorten the life cycle of a product and expand the market's boundaries, creating several medical sector opportunities.

Market Dynamics

The global immunoprotein diagnostic testing market is growing owing to the rising prevalence of obesity, rheumatoid arthritis, cancer, type 2 diabetes, infectious diseases, and cardiovascular disease.

Rising technological advancements and rising prevalence of obesity, rheumatoid arthritis, cancer is expected to drive market growth.

According to the World Health Organization (WHO), it has been projected that, by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and that 71% of deaths are due to ischaemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. The number of people in the developing world with diabetes will increase by more than 2.5-fold, from 84 million in 1995 to 228 million in 2025. On a global basis, 60% of the burden of chronic diseases will occur in developing countries. Indeed, cardiovascular diseases are even now more numerous in India and China than in all the economically developed countries in the world put together. As for overweight and obesity, not only has the current prevalence already reached unprecedented levels, but the rate at which it is annually increasing in most developing regions is substantial. The public health implications of this phenomenon are staggering and are already becoming apparent. Hence, the rising prevalence of chronic diseases has raised the demand for rapid diagnosis.

The rising geriatric population coupled with an all-time high incidence of chronic diseases has given an impetus to the global market's growth for immunoprotein diagnostic testing. Moreover, the upswing in demand for immunoprotein diagnostic testing can also be attributed to the prevalence of infectious diseases worldwide. Unhygienic living conditions, especially in underdeveloped regions, have also led to diseases and infections. This has brought the global market for immunoprotein diagnostic testing under the spotlight of attention.

High cost of diagnostic tests is expected to hamper the market growth.

The regulatory framework is very complex and doesn't approve many immunoprotein diagnostic tests easily and high cost of some diagnostic tests can hamper the growth of the market.

Industry Analysis

The global Immunoprotein Diagnostic Testing market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Product Innovation, Unmet Needs.

Segment Analysis

Enzyme based immunoassay segment is expected to hold the largest market share in global immunoprotein diagnostic testing market

Based on technology, the immunoprotein diagnostic testing market is segmented into enzyme-based immunoassay, radioimmunoassay, immunoprotein electrophoresis, chemiluminescence assay, immunofluorescence assay, immunoturbidity assay, and others. Among these, enzyme-based immunoassay (EIA) accounted for the largest market share. EIA has used a diagnostic and quality tool in several laboratories and companies. Also, some of the major companies are developing new products with EIA technology. For instance, Abcam offers Human Complement C3 ELISA Kit for diagnosis.

On the other hand, chemiluminescence assay is expected to grow at the highest growth rate during the forecast period, owing to its features such as high sensitivity and specificity, strong ability to detect antigens in human serum & plasma samples. Chemiluminescence assay is an important tool for the instant diagnosis of several diseases and is ascertained to be more accurate than fluorescence-based detection of labeled probes. On November 6th, 2019, ALPCO has launched its STELLUX Chemi Glucagon ELISA. The new chemiluminescence ELISA features increased analytical specificity and a broad range to accurately quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL) in human and rodent samples.

Based on application, the immunoprotein diagnostic testing is be segmented into autoimmune disease testing, infectious disease testing, oncology testing, allergy testing, toxicology testing, and endocrine testing. Among these, oncology testing accounted for the largest market share, with rising demand over the forecast period. The presence of various diagnostic methods, such as Epidermal Growth Factor Receptor (EGFR) testing, helps detect mutations in the EFGR gene, which occurs in patients with non-small cell lung cancer, and this helps in treatment planning. In March 2019, NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, launched the Ventana PD-L1 (SP142) Assay for tumor tissue from patients with a triple-negative subtype of breast cancer. This PD-L1 assay is a companion diagnostic test recently approved by the FDA to identify advanced, metastatic triple-negative breast carcinoma cancer patients who may respond to the immune checkpoint inhibitor therapy TECENTRIQ (atezolizumab) used in combination with chemotherapy. TECENTRIQ is the first immunotherapy approved specifically for breast cancer.

Geographical Analysis

North America region holds the largest market share in the global immunoprotein diagnostic testing market

North America is dominating the global immunoprotein diagnostic testing market accounted for the largest market share, owing to rising incidences of chronic diseases, rising to high demand for diagnostic systems. According to the Centers for Disease Control and Prevention (CDC), chronic diseases are the leading cause of death and disability in the United States. About 133 million Americans, i.e., 45% of the population, have at least one chronic disease. Chronic diseases are responsible for seven out of every 10 deaths in the U.S., killing more than 1.7 million Americans every year. By 2025, chronic diseases will affect an estimated 164 million Americans. People with chronic conditions are the most frequent users of health care in the U.S. They account for 81% of hospital admissions, 91% of all prescriptions filled, and 76% of all physician visit. In another instance, the American Cancer Society projected around 1,806,590 new cancer cases and 606,520 cancer deaths in the United States in the year 2020. Because of such a projection, accurate and fast diagnosis of such chronic diseases is needed to help diminish the high mortality rate. Immunoprotein diagnostic devices and reagents have proven to be extremely efficacious in the rapid detection of chronic disorders. Medical practitioners in the US and Canada have continuously focused on developing new immunoprotein testing.

Competitive Landscape

Some of the major players in the immunoprotein diagnostic testing market include F. Hoffmann-La Roche Ag, Abcam PLC, Abbott Laboratories, Diasorin, Enzo Life Sciences, Randox Laboratories, Siemens, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc, Danaher Corporation, Ortho Clinical Diagnostics, among others.

The key players are adopting various growth strategies such as expansion, mergers & acquisitions, partnerships, product launches, and collaborations contributing to the Immunoprotein Diagnostic Testing market globally. For instance,

  • In July 2019, the U.S. Food and Drug Administration (FDA) cleared for marketing four previously cleared tests with new indications to aid in diagnosing Lyme disease. The tests cleared are the first time that a test has been indicated to follow a new testing paradigm in which two tests called enzyme immunoassays (EIA) are run concurrently or sequentially, rather than the current two-step process in which a separate protein test called a Western Blot must be run after the initial EIA test.

Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

The Afinion 2: It is an analyser that is a compact, rapid and can perform multi-assay which gives important near patient diagnosis or testing at the point-of-care.

Key Developments: In Oct 2020, Abbott got emergency use authorization for their COVID-19 IgM antibody blood test from the FDA.

The global immunoprotein diagnostic testing market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. Rising technological advancements and rising prevalence of obesity, rheumatoid arthritis, cancer
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of the device and maintenance
      • 4.1.2.2. Risk of injuries in surgery
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Product Innovations
  • 5.6. Unmet Needs

6. By Test Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type Segment
    • 6.1.2. Market Attractiveness Index, By Test Type Segment
  • 6.2. Immunoglobulin Diagnostic Tests
      • 6.2.1.1. Introduction
      • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 6.3. C-Reactive Protein (CRP) Diagnostic Tests
  • 6.4. Complement System Proteins Diagnostic Tests
  • 6.5. Free Light Chain Diagnostic Tests
  • 6.6. Haptoglobin Diagnostic Tests
  • 6.7. Prealbumin Diagnostic Tests
  • 6.8. Others

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 7.1.2. Market Attractiveness Index, By Application Segment
  • 7.2. Autoimmune Disease Testing
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Infectious Disease Testing
  • 7.4. Oncology Testing
  • 7.5. Allergy Testing
  • 7.6. Toxicology Testing

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
    • 8.1.2. Market Attractiveness Index, By Technology Segment
  • 8.2. Enzyme Based Immunoassay
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Radioimmunoassay
  • 8.4. Immunoprotein Electrophoresis
  • 8.5. Chemiluminescence assay
  • 8.6. Immunofluorescence Assay
  • 8.7. Immunoturbidity Assay
  • 8.8. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospital and clinics
      • 9.2.1.1. Introduction
      • 9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Diagnostic laboratories
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By S Test Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Test Type Test Types Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Abbott Laboratory
    • 12.1.1. Company Overview
    • 12.1.2. Test Type Test Type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Thermo Fisher Scientific Inc
  • 12.3. Bio-Rad Laboratories, Inc
  • 12.4. Danaher Corporation
  • 12.5. F. Hoffmann-La Roche Ag
  • 12.6. Enzo Biochem, Inc
  • 12.7. Siemens Aktiengesellschaft
  • 12.8. Ortho Clinical Diagnostics
  • 12.9. Diasorin S.P.A
  • 12.10. Abcam Plc

LIST NOT EXHAUSTIVE

13. Global Immunoprotein Diagnostic Testing Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and End User
  • 13.3. Contact Us